2025年
- November 19, 2025
- World's First Mitochondrial Disease Treatment 'MA-5' Commences Phase II Clinical Trial
- November 7, 2025
- パチスロ ま ど マギ 3 for Second Quarter (Interim Period) of FY2025 - Supplementary Information
- October 16, 2025
- Announcement of Presentation in Academic Conference Regarding Result of Specified Clinical Trial using Digital Therapeutics for Tinnitus
- October 1, 2025
- パチスロ ま ど マギ 3 and Hinge Bio Enter into a Collaboration and License Agreement of HB2198 in Japan for SLE and other diseases
- September 16, 2025
- Topline Results from Phase 3 Clinical Study of KRP-R120 for Interstitial Lung Disease
- July 31, 2025
- Summary of パチスロ ま ど マギ 3 (For the First Quarter ended June 30, 2025) [Under Japanese GAAP]
- May 21, 2025
- Notice of Dividends from Retained Earnings
- May 12, 2025
- パチスロ ま ど マギ 3 for the Fiscal Year Ended March 31, 2025 (May 12 2025) - Supplementary Information
- May 12, 2025
- Notice Regarding Cancellation of Treasury Stock
- May 12, 2025
- Announcement of Executive Personnel Changes
- April 23, 2025
- Notice of Upward Revisions to Earnings Forecasts
- February 25, 2025
- Digital Therapeutic Development for Chronic Cough Treatment
- 1